Literature DB >> 11115358

Role of RANTES in experimental cardiac allograft rejection.

M S Mulligan1, J E McDuffie, T P Shanley, R F Guo, J Vidya Sarma, R L Warner, P A Ward.   

Abstract

The host response to alloantigen results in upregulation of Class II MHC antigens and associated cytokine production (especially IL-2 and interferon-gamma (IFN-gamma)) as well as lymphocytic infiltration and cellular activation which leads to graft damage/destruction. RANTES (Regulated upon Activation, Normal T-cell Expressed and presumably Secreted) is a member of the beta subfamily (CC) of chemokines and has been shown to function as a lymphocyte chemoattractant. We now describe the requirement for RANTES in cardiac heterotopic allograft (brown Norway into Lewis rats) rejection in rats. By Northern blot analysis, mRNA could be detected in allografts at 6 and 8 days post-transplantation but not in isogenic (Lewis) grafts. RANTES protein could be demonstrated by Western blot analysis in homogenates from allografts at day 8 but not at day 0 and could not be identified in isogenic cardiac transplants. By immunostaining, RANTES protein was present in mononuclear cells of allografts at day 6 but was absent in the isogenic transplants. When rats were treated with anti-RANTES serum, there was a significant delay in rejection time (cessation of beating) of the allografts. These data demonstrate that expression of RANTES in rat cardiac allografts is linked to the rejection phenomenon. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115358     DOI: 10.1006/exmp.2000.2327

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

1.  Changes of inducible protein-10 and regulated upon activation, normal T cell expressed and secreted protein in acute rejection of pancreas transplantation in rats.

Authors:  Jun Zhu; Ze-Kuan Xu; Yi Miao; Xun-Liang Liu; Hong Zhang
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

2.  Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.

Authors:  Christophe Blanchetot; Dennis Verzijl; Azra Mujić-Delić; Leontien Bosch; Louise Rem; Rob Leurs; C Theo Verrips; Michael Saunders; Hans de Haard; Martine J Smit
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

3.  Heterogeneity of endothelial cells from different organ sites in T-cell subset recruitment.

Authors:  Yaw-Chyn Lim; Guillermo Garcia-Cardena; Jennifer R Allport; Mandy Zervoglos; Andrew J Connolly; Michael A Gimbrone; Francis W Luscinskas
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

4.  Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection.

Authors:  C A Haskell; W W Hancock; D J Salant; W Gao; V Csizmadia; W Peters; K Faia; O Fituri; J B Rottman; I F Charo
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

5.  CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation.

Authors:  Sung W Choi; Gerhard C Hildebrandt; Krystyna M Olkiewicz; David A Hanauer; Meghana N Chaudhary; Ines A Silva; Clare E Rogers; Daphne T Deurloo; Jacki M Fisher; Chen Liu; David Adams; Stephen W Chensue; Kenneth R Cooke
Journal:  Blood       Date:  2007-07-19       Impact factor: 22.113

6.  Myocardial Gene Expression Profiling to Predict and Identify Cardiac Allograft Acute Cellular Rejection: The GET-Study.

Authors:  Diane Bodez; Hakim Hocini; Nicolas Tchitchek; Pascaline Tisserand; Nicole Benhaiem; Caroline Barau; Mounira Kharoubi; Aziz Guellich; Soulef Guendouz; Costin Radu; Jean-Paul Couetil; Bijan Ghaleh; Jean-Luc Dubois-Randé; Emmanuel Teiger; Luc Hittinger; Yves Levy; Thibaud Damy
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

7.  Immunological and inflammatory mapping of vascularized composite allograft rejection processes in a rat model.

Authors:  Or Friedman; Narin Carmel; Meirav Sela; Ameen Abu Jabal; Amir Inbal; Moshe Ben Hamou; Yakov Krelin; Eyal Gur; Nir Shani
Journal:  PLoS One       Date:  2017-07-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.